Advocacy for Regulatory Flexibility in Rare Disease Therapies

Industry leaders specializing in rare diseases convened in Washington, D.C., to advocate for increased regulatory flexibility for therapies targeting uncommon medical conditions. This pivotal meeting was prompted following recent drug rejections involving companies like Biohaven and Saol Therapeutics.

During a briefing before the Congressional Mitochondrial Disease House Caucus, Sara Klock from Holland & Knight highlighted the FDA's draft guidance on the Plausible Mechanism Pathway. She expressed optimism, stating that it illustrates the FDA's willingness to be more flexible in their standards, providing hope to the industry, according to BioSpace reports.

However, recent actions by the FDA have signaled a stricter regulatory stance. Companies such as Capricor Therapeutics, Replimune, and uniQure have faced challenges due to perceived reversals in FDA guidance. At a Senate hearing, Jeremy Schmahmann from Harvard Medical School criticized FDA communications as difficult, while FDA Commissioner Marty Makary underscored rigorous oversight standards, particularly in cell and gene therapy.

The briefing, co-hosted by the United Mitochondrial Disease Foundation (UMDF), focused on pyruvate dehydrogenase complex deficiency (PDCD) and the rejection of Saol's SL1009 drug. The FDA's complete response letter called for an additional clinical trial, which CEO Dave Penake considered impractical. He stressed the need for regulatory leniency due to the disease's impact, expressing hope that Congressional oversight would expedite approval.

Saol plans a Type C meeting with the FDA in March, aiming to accelerate progress amid a limited drug supply. Concurrently, Biohaven is navigating regulatory hurdles with its candidate troriluzole for spinocerebellar ataxia (SCA), which the FDA rejected despite positive trial outcomes. Biohaven remains confident in its data, seeking further review from the Center for Drug Evaluation and Research.

Both PDCD and SCA represent ultra-rare, progressive conditions misaligned with FDA timelines, remarked Penake. He emphasized the severity and rapid progression noted in PDCD patients, including marked improvements in mobility and communication. Patricia Greenstein from Harvard Medical School highlighted the consequences of therapy delays for SCA patients, stressing the need for timely solutions to avert irreversible decline.